EU Approval of Humira Biosimilar, ABP501, to Treat Adults and Children with IBD Favored

EU Approval of Humira Biosimilar, ABP501, to Treat Adults and Children with IBD Favored
ABP501, a biosimilar of Humira (adalimumab), was recommended for approval in the European Union to treat adults and some children with various inflammatory diseases, including inflammatory bowel disease (IBD), by the Committee for Medicinal Products for Human Use (CHMP). CHMP, an arm of the European Medicines Agency (EMA), issued its positive opinion for ABP 501 as a treatment for adults with IBD, including moderate-to-severe Crohn's disease and ulcerative colitis, rheumatoid arthritis and psoriatic arthritis (PA), among other diseases. The opinion also recommends the treatment for certain p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *